Biogen Inc (BIIB34)

187.63
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    187.63/0.00
  • Day's Range:
    187.63 - 187.63

BIIB34 Overview

Prev. Close
184.23
Day's Range
187.63-187.63
Revenue
-
Open
187.63
52 wk Range
157.76-313.69
EPS
14.01
Volume
0
Market Cap
161.37B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
292
P/E Ratio
15.10
Beta
0.387
1-Year Change
-35.62%
Shares Outstanding
145,113,047
Next Earnings Date
-
What is your sentiment on Biogen DRC?
or
Market is currently closed. Voting is open during market hours.

Biogen Inc Company Profile

Biogen Inc Company Profile

Employees
9100
Market
Brazil
  • Type:Equity
  • Market:Brazil
  • ISIN:BRBIIBBDR001

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyBuyNeutral
Technical IndicatorsBuyStrong BuyStrong BuyBuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuySell